Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Embla Medical hfOSSFF -0.55%87 Future 3-5Y EPS without NRI Growth Rate is 14.87 as of Sep. 13, 2026. GuruFocus rates OSSFF with a GF Score™ of 87/100 and a GF Value™ of $5.29 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 286 Medical Devices & Instruments companies, Embla Medical hf ranks worse than 63.99% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate is 14.87.
Embla Medical hf (OTCPK:OSSFF) Future 3-5Y EPS without NRI Growth Rate Explanation
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
Embla Medical hf Future 3-5Y EPS without NRI Growth Rate Related Terms
OSSFF vs ABT, SYK, MDT: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Medical Devices subindustry, Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Embla Medical hf Future 3-5Y EPS without NRI Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 14.87 mean?
Embla Medical hf (OSSFF) has a Future 3-5Y EPS without NRI Growth Rate of 14.87 as of Sep. 13, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Embla Medical hf and its competitors. According to the industry distribution chart, Embla Medical hf ranks #183 out of 286 companies in the Medical Devices & Instruments industry, placing it in the top 64%.
Is Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate too high?
Embla Medical hf's current Future 3-5Y EPS without NRI Growth Rate is 14.87. The Medical Devices & Instruments industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Embla Medical hf's value of 14.87 is 28.4% below this industry median. Based on the distribution chart, Embla Medical hf ranks #183 out of 286 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Embla Medical hf has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Future 3-5Y EPS without NRI Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Embla Medical hf ranks #183 out of 286 companies for Future 3-5Y EPS without NRI Growth Rate. This places Embla Medical hf in the lower half of its industry. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.78. Embla Medical hf's value of 14.87 is 28.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Medical Devices & Instruments company?
The median Future 3-5Y EPS without NRI Growth Rate among Medical Devices & Instruments companies is 20.78, based on 286 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Embla Medical hf's current Future 3-5Y EPS without NRI Growth Rate of 14.87 is 28.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for Embla Medical hf and its competitors. For the Medical Devices & Instruments industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Embla Medical hf's current Future 3-5Y EPS without NRI Growth Rate is 14.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OSSFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.29, compared to a current price of $4.53 — trading 14.5% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 14.87 and 28.4% below the Medical Devices & Instruments industry median of 20.78. Embla Medical hf's overall GF Score™ is 87/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Future 3-5Y EPS without NRI Growth Rate is 14.87 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Embla Medical hf (OSSFF) Overvalued in 2026?
Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued.
The current stock price of $4.53 is trading 14.5% below its estimated GF Value™ of $5.29.
GuruFocus considers Embla Medical hf to be Modestly Undervalued.
Key valuation signals for OSSFF:
Future 3-5Y EPS without NRI Growth Rate: 14.87
GF Value™: $5.29 vs. price of $4.53 (14.5% below fair value)
Industry Position: 28.4% below the Medical Devices & Instruments median (#183 of 286)
No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
87GF Score
Get the complete analysis for OSSFF
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSSFF has been successfully added to your 
